Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam

Launched by UNIVERSITY OF MEDICINE AND PHARMACY AT HO CHI MINH CITY · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well certain tests can help identify Lynch Syndrome in patients with colorectal cancer (CRC) in Vietnam. Lynch Syndrome is a genetic condition that increases the risk of developing various cancers, including CRC. The study will involve Vietnamese patients aged 18 to 70 who are scheduled for a colonoscopy due to suspicious findings. Participants will fill out a medical history questionnaire and provide blood samples for genetic testing. Additionally, samples from their tumors will be analyzed to check for specific genetic changes that could indicate Lynch Syndrome.

To be eligible for the trial, participants must be between 18 and 70 years old, agree to take part in the study, and have a confirmed diagnosis of adenocarcinoma (a type of cancer) from their biopsy. However, individuals with active bleeding issues, those taking certain blood-thinning medications, or those with problems controlling bleeding will not be able to participate. This study is not yet recruiting participants, but it aims to improve how we detect Lynch Syndrome, which could lead to better prevention and treatment options for patients with CRC.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 18 to 70 years
• • Provide informed consent to participate in the study
• • Undergo colonoscopy with endoscopic findings suspicious for CRC
• • Have biopsy-confirmed adenocarcinoma through colonoscopic biopsy
• Exclusion Criteria:
• • Active gastrointestinal bleeding
• • Currently using anticoagulants or antiplatelet agents
• • History of coagulation disorders or difficulty controlling bleeding
• • Incomplete colonoscopy to the cecum (excluding cases of tumor-induced obstruction)